SCHEDULE: Vestal Point Capital Reduces Dianthus Therapeutics Stake

Vestal Point Capital and Ryan Wilder have reduced their beneficial ownership in Dianthus Therapeutics, Inc. to 3.0% as of September 30, 2025.

Summary

• Vestal Point Capital, LP and Ryan Wilder, collectively referred to as the Reporting Persons, have filed an Amendment No. 2 to their Schedule 13G.
• The filing indicates a beneficial ownership of 1,180,000 shares of Common Stock in Dianthus Therapeutics, Inc. /DE/.
• This represents 3.0% of the company's outstanding Common Stock.
• The percentage is calculated based on 39,804,361 shares outstanding as of September 11, 2025, following a public offering and full exercise of the underwriter's option.
• The event triggering this filing occurred on September 30, 2025.
• The Reporting Persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the implied reduction in a significant institutional investor's stake below the 5% threshold, which can be interpreted as a loss of conviction or a strategic divestment.

Positives

• NA

Negatives

• The reduction in beneficial ownership by a significant institutional investor (Vestal Point Capital, LP and Ryan Wilder) from a previous stake (implied to be 5% or more) to 3.0% could be perceived negatively by the market, suggesting a decreased conviction in the company's future prospects by this specific investor.

Risks

• The filing itself does not detail specific company risks, but a reduction in institutional ownership can signal a perceived increase in investment risk by the selling entity or a reallocation of capital to other opportunities.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Dianthus Therapeutics, Inc. or the Reporting Persons regarding the company's future outlook.

Industry Context

This filing reflects a change in a specific institutional investor's position in Dianthus Therapeutics, Inc. and does not provide broader industry trends or competitive analysis. The reduction in stake by Vestal Point Capital, LP could be due to portfolio rebalancing, a change in investment strategy, or a revised assessment of Dianthus Therapeutics' prospects relative to other opportunities in the biotechnology or pharmaceutical sector.

Stakeholder Impact

• Shareholders: May interpret the reduction in institutional ownership as a negative signal, potentially influencing their investment decisions.
• Company Management: May need to understand the reasons behind the divestment by Vestal Point Capital, LP, though the filing states the acquisition was not for influencing control.

Key Dates

Recommendation

The filing indicates a reduction in a significant institutional investor's stake in Dianthus Therapeutics, Inc. to 3.0%. While this is a factual disclosure of ownership change and not a direct assessment of the company's fundamentals, a reduction below the 5% threshold by a previously significant holder can be a negative market signal. Without additional information on the company's performance, industry outlook, or the investor's specific reasons for divestment, a 'hold' recommendation is prudent. Investors should monitor future company announcements and broader market sentiment, as this reduction might suggest a re-evaluation of the investment by a sophisticated party.

Keywords

Dianthus Therapeutics, Vestal Point Capital, Ryan Wilder, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Equity Stake, SEC Filing